Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer

NCT03179410 is registered in ClinicalTrials.gov with Andrew J. Armstrong, MD as lead sponsor.

NCT NCT03179410
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03179410 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PD-L1 Inhibition as ChecKpoint Immunotherapy for NeuroEndocrine Phenotype Prostate Cancer
Lead sponsor
Andrew J. Armstrong, MD
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2018
Completion date
December 18, 2020
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer